Memorial Sloan Kettering Cancer Center (MSK) is a research hospital dedicated to cancer research, training and patient care. Radiotheranostics combines the use of one radioactive drug to identify and target a cancer tumor and a second radioactive drug to deliver cancer-destroying therapy to the tumor. Recent advances make possible the use of exponentially more powerful alpha-emitting particles in this process, potentially revolutionizing the precision treatment of cancer and limiting damage to healthy cells for better patient outcomes. Manufacturing, storing and utilizing these particles requires new investments in technology and specialized labs. This funding supports MSK in the creation of the first radiotheranostic program with its own alpha lab at a US academic institution.
